ClinicalTrials.gg
CompletedNCT07935044Updated Nov 13, 2026

The Analgesic Effects of Chest Orthosis Application in Costal Fractures

An interventional study of Chest orthosis and Ibuprofen in The Focus of the Study is the Effectiveness of the Chrisofix® Chest Orthesis (CCO) in Patients With Costal Fractures, sponsored by Ankara City Hospital Bilkent. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Primary conditionnone(registry's first term: Emergencies)No conditionIs this wrong?Emergencies describes something many studies share rather than a condition a study is about. The study names no condition we can place it under, so it is not compared with other studies by condition.

Sponsored by Ankara City Hospital Bilkent · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Sep 2024, registered Jan 2025).
Updated Nov 13, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Rib fractures are a common cause of acute pain after blunt chest trauma. In the emergency department, pain is usually managed with a multimodal approach including nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, local anesthetic sprays, patches and nerve blocks. Systemic analgesics may cause gastrointestinal, renal and hepatic adverse effects, and opioids carry the risk of respiratory depression and dependence. External chest wall stabilization with a rib orthosis may reduce pain by stabilizing the fracture with fewer systemic adverse effects.

This randomized, open-label, controlled trial compares the Chrisofix Chest Orthosis (CCO) combined with ibuprofen versus ibuprofen alone in adult patients presenting to the emergency department with fewer than three rib fractures. Pain intensity (Numeric Rating Scale), functional limitation, analgesic consumption and adverse events are assessed during emergency department observation and during a 7-day post-discharge follow-up.

02

Conditions studied

  • The Focus of the Study is the Effectiveness of the Chrisofix® Chest Orthesis (CCO) in Patients With Costal Fractures

Browse trials for

Keywords

  • The Chrisofix® Chest Orthesis (CCO)
  • pain management
  • emergency department
  • blunt chest trauma
03

In context

Lead sponsor

Ankara City Hospital Bilkent is the lead sponsor of 445 studies on the registry; 107 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

IInclusion Criteria:

  • Age 18 years or older
  • Presentation to the emergency department within 24 hours after blunt thoracic trauma
  • Radiologically confirmed rib fracture (fewer than three fractures)
  • Hemodynamically stable
  • Able to provide written

Exclusion Criteria:

  • Pregnancy or suspected pregnancy
  • to nonsteroidal anti-inflammatory drugs (e.g., peptic ulcer disease, active bleeding, renal failure)
  • Pneumothorax and/or hemothorax
  • Intra-abdominal organ injury or penetrating chest trauma
  • Three or more rib fractures, bilateral rib fractures, or fractures involving multiple regions of the chest wall
  • Skin lesion, active skin infection, or history of allergy to adhesive materials at the orthosis application site
  • Altered mental status or psychiatric disease severe enough to impair cooperation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Chest orthosis + ibuprofen

    Standard emergency department analgesia (ibuprofen 400 mg intravenous infusion in 150 mL isotonic saline over 15 minutes), followed by application of a Chrisofix Chest Orthosis over the fractured rib, worn continuously for up to 10 days. After discharge, oral ibuprofen 600 mg as needed for pain, up to a maximum of 4 doses per day.

    Device: Chest orthosis · Drug: Ibuprofen

  • Active comparator
    Ibuprofen only

    Ibuprofen 400 mg intravenous infusion in the emergency department, followed after discharge by oral ibuprofen 600 mg tablets taken only when pain is present, up to a maximum of 4 doses per day.

    Drug: Ibuprofen

Interventions

  • DeviceChest orthosis

    Commercially available self-adhesive carbon composite chest orthosis (Chrisofix AG, Switzerland) applied over the fractured rib according to the manufacturer's instructions, without circumferential chest compression; worn continuously for up to 10 days, removed only for hygiene or skin irritation.

  • Ibuprofen 400 mg intravenous infusion in the emergency department, followed by oral ibuprofen 600 mg as needed (maximum 4 doses/day) after discharge.

06

What researchers measure

Primary outcomes

  1. Pain Intensity on the Numeric Rating Scale (NRS) During Emergency Department Observation

    Pain intensity measured with the 11-point Numeric Rating Scale (NRS; 0 = no pain, 10 = worst imaginable pain). Higher scores indicate worse pain. NRS scores will be recorded at each time point and compared between the chest orthosis and control groups.

    Time frame: 0, 30 and 60 minutes after initiation of emergency department analgesia

  2. Pain Intensity on the Numeric Rating Scale (NRS) During 7-Day Post-Discharge Follow-up

    Pain intensity measured with the 11-point Numeric Rating Scale (NRS; 0 = no pain, 10 = worst imaginable pain). Higher scores indicate worse pain. NRS is assessed by daily telephone interview on days 1 to 6 and at the face-to-face visit on day 7 after discharge, and compared between the chest orthosis and control groups.

    Time frame: Daily from day 1 through day 7 after discharge from the emergency department

  3. Functional Limitation Score During 7-Day Post-Discharge Follow-up

    Functional limitation measured with a study-specific 5-item form assessing pain and/or dyspnea during walking, climbing stairs, sitting down or standing up, normal breathing, and awakening from sleep. Each item is scored 0 to 3; total score ranges from 0 (no limitation) to 15 (severe limitation). Higher scores indicate greater functional impairment. Assessed daily by telephone on days 1 to 6 and face-to-face on day 7, and compared between the chest orthosis and control groups.

    Time frame: Daily from day 1 through day 7 after discharge from the emergency department

Secondary outcomes

  1. Number of Participants Requiring Rescue Analgesia in the Emergency Department

    Number of participants with an NRS score of 4 or higher at the 60-minute assessment who received protocol-defined rescue analgesia (intravenous tramadol 50 mg, increased to 100 mg if needed, followed by intravenous fentanyl 50 micrograms as second-line treatment).

    Time frame: 60 minutes after initiation of emergency department analgesia

  2. Total Oral Analgesic Consumption During 7-Day Post-Discharge Follow-up

    Total number of oral ibuprofen 600 mg tablets taken by each participant after discharge, as reported during daily telephone follow-up on days 1 to 6 and at the face-to-face visit on day 7. Compared between the chest orthosis and control groups.

    Time frame: From discharge through day 7

  3. Number of Participants With Treatment- or Orthosis-Related Adverse Events

    Number of participants reporting at least one adverse event, including nausea, vomiting, itching, redness, skin irritation, or respiratory symptoms (fever, cough, sputum production, dyspnea), recorded during emergency department observation and daily follow-up through day 7.

    Time frame: From enrollment through day 7 after discharge

07

Study locations

1 site
  • Ankara CH
    Ankara, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2024 to primary completion in Aug 2025, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2025
First posted
Nov 13, 2026
StartActual
Sep 1, 2024
Primary completionActual
Aug 1, 2025
CompletionActual
Sep 1, 2025
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07935044
Responsible party
Ahmet Burak Erdem, MD (Associate Professor of Emergency Medicine, Ankara Etlik City Hospital) — Principal investigator
First posted
Nov 13, 2026
Start date
Sep 1, 2024
Primary completion
Aug 1, 2025
Completion
Sep 1, 2025
Last update
Nov 13, 2026

Study contacts

Ahmet Burak Erdem, Associate Professor
study director · Ankara Etlik City Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion